![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Data from animal models indicate that endothelin (ET) receptor antagonists may have therapeutic utility in hypertension, myocardial infarction and subsequent reperfusion injury, acute renal failure and asthma. Selective antagonists for the two receptor subtypes (ETa and ETb) are now available. Nonpeptide ETA-selective antagonists are now available and have the potential of developing into orally active agents in clinical studies.